In-depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
by Hailey
No Comments
cardiac remodeling after myocardial infarction (MI) is a maladaptive changes associated with progressive heart failure and compromise the long-term clinical outcomes. Most of the patients afflicted by MI still developing adverse outcomes associated with cardiac remodeling. Therefore, it is important to identify biomarkers for early prediction of cardiac remodeling. An in-depth proteomic approaches, including both an array of semi-quantitative and quantitative antibody, is used to identify circulating biomarkers that may be associated with adverse cardiac remodeling.
Furthermore, the statistical correlation analysis was conducted between biomarker candidates and clinical cardiac remodeling the data to demonstrate their clinical utility. A proteomics systematic approach revealed that sclerostin (SOST), differentiation of growth factor-15 (GDF-15), urokinase-type plasminogen activator (uPA) and midkine (MK) increases, while monocytes chemotactic protein – 3 (MCP- 3 ) is a unique decreased in patients who develop cardiac remodeling MI, compared with patients with MI not develop cardiac remodeling and healthy humen.
In addition, the analysis of the correlation between the proteomes of serum and cardiac remodeling parameters of echocardiography showed a positive relationship moderate between left ventricular indexes end-diastolic volume (LVEDVi) and three serum protein , uPA, MK and GDF-15 (P <0 , 05, respectively), and moderate negative correlation between LV ejection fraction (LVEF) and serum is protein (P <0.05, respectively). Importantly, uPA and MK were first identified associated with the development of cardiac remodeling. The research contributes to a better understanding of various cytokines expressed during adverse cardiac remodeling. biomarkers identified could facilitate the early identification of patients at high risk for ischemic heart failure awaiting further confirmation through larger clinical trials.
Prevention of severe intestinal dysfunction Through Barrier Single-Species Probiotic Is Associated With Microbiome-Mediated Activation of Glutamate-Glutamine Biosynthesis Introduction: Intra-abdominal hypertension (IAH), the leading complications in the intensive care unit, significantly disrupt the intestinal microbial composition by reducing the relative abundance of Lactobacillus and increasing the relative abundance of opportunistic infectious bacteria.
In-depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
Method: In order to evaluate the preventive effect of probiotic-based Lactobacillus at IAH-induced damage intestinal barrier, a-single species of probiotics (L92) and multi-species probiotics (VSL # 3 ) is introduced orally to rats Sprague-Dawley 7 days before inducing IAH. Histology intestine and permeability to macromolecules (isothiocyanate fluoresceine, FITC-dextran, N = 8 for each group), parameter immunomodulatory and response to oxidative [ monocytes chemotactic protein 1 (MCP-1), interleukin-1β (IL-1β), interleukin-4 (IL-4), interleukin-10 (IL-10), malonaldehyde (MDA), glutathione peroxidase (GSH- Px), catalase (CAT) and superoxide dismutase (SOD); N = 4 for each group], and profiling microbiome (N = 4 per group) were analyzed.
Results: 7 days pretreatments of L92 significantly reduced IAH-induced increase in intestinal permeability to FITC-dextran and histological damage (P <0.0001), accompanied by the suppression of inflammation and oxidative activation. Increased MCP-1 and IL-1β was significantly inhibited (P <0.05); anti-inflammatory cytokine, IL-4 and IL-10 were maintained at a high level; and oppression CAT (P <0.05) significantly reversed when pretreated with L92.
-MCPG)
-MCPG)
)
)
-MCPG disodium salt)
, hydroxyethanesulfonate: (50mg))
)
)
): (50mg))
)
)
 Antibody)
 Antibody)
 Antibody)
-(+)-7,7'-Bis(Diphenylphosphino)-2,2',3,3'-Tetrahydro-1,1'-Spirobiindane)
-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid)
)
)
2)
)
2)
)
)
